SCHEMBL14303613

SCHEMBL14303613

O=C(c1ccc(Cl)cc1)c1ncc(Cl)cc1NSc1ccc(Cl)c(C(F)(F)F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C9 P11712 2/20 0.43
▸ KDR P35968 5/20 0.43
▸ BRAF P15056 4/20 0.43
▸ FLT3 P36888 3/20 0.43
▸ KIT P10721 2/20 0.43
▸ GLA P06280 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ CYP1A2 P05177 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ NPSR1 Q6W5P4 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ EGFR P00533 1/20 0.36
▸ CYP3A4 P08684 2/20 0.36
▸ CHEK2 O96017 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12347516 0.84 CYP2C9 (0.41) CYP2C9KDRBRAFFLT3KIT
SCHEMBL12347487 0.83 CYP2C9 (0.41) CYP2C9KDRBRAFFLT3KIT
SCHEMBL13958200 0.80 BRAF (0.49) CYP2C9KDRBRAFFLT3KIT
SCHEMBL306522 0.78 CYP2C9 (0.67) CYP2C9CYP3A4CCR2
SCHEMBL14302510 0.78 CYP2C9 (0.39) CYP2C9KDRBRAFNPSR1HTT
SCHEMBL14310292 0.78 CDK8 (0.40) CYP2C9KDRBRAFFLT3KIT
SCHEMBL14302514 0.76 KCNN4 (0.35) CYP2C9KDRBRAFFLT3KIT
SCHEMBL14310293 0.73 ALDH1A1 (0.38) MAPTCCR2NPC1CNR2
SCHEMBL305754 0.71 CYP2C9 (0.66) CYP2C9CYP3A4CCR2
SCHEMBL305568 0.71 CYP2C9 (0.65) CYP2C9CYP3A4CCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008008431-A2 HETEROARYL SULFONAMIDES AND CCR2/CCR9 CHEMOCENTRYX, INC. (US) 2008-01-17 — — WO disclosed
Send feedback